KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Receivables (2016 - 2025)

Emergent BioSolutions' Receivables history spans 16 years, with the latest figure at $102.4 million for Q4 2025.

  • For Q4 2025, Receivables fell 33.94% year-over-year to $102.4 million; the TTM value through Dec 2025 reached $102.4 million, down 33.94%, while the annual FY2025 figure was $102.4 million, 33.94% down from the prior year.
  • Receivables reached $102.4 million in Q4 2025 per EBS's latest filing, down from $168.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $330.5 million in Q4 2021 to a low of $102.4 million in Q4 2025.
  • Average Receivables over 5 years is $221.0 million, with a median of $223.8 million recorded in 2022.
  • Peak YoY movement for Receivables: soared 38.02% in 2021, then tumbled 49.46% in 2025.
  • A 5-year view of Receivables shows it stood at $330.5 million in 2021, then crashed by 34.52% to $216.4 million in 2022, then increased by 12.01% to $242.4 million in 2023, then crashed by 36.06% to $155.0 million in 2024, then crashed by 33.94% to $102.4 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Receivables are $102.4 million (Q4 2025), $168.8 million (Q3 2025), and $102.7 million (Q2 2025).